Quantitative Total Extensible Imaging (QTxI)

by AIQ Solutions  · Based in United States → — Optimizing late-stage cancer care with technology-enabled service.
Nuclear Medicine Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Quantitative Total Extensible Imaging (QTxI) is a software tool developed by AIQ Solutions to aid trained medical professionals in the evaluation and information management of digital medical images. Cleared by the FDA, QTxI is designed for use by radiologists, oncologists, nuclear medicine physicians, medical imaging technologists, dosimetrists, and physicists. The software operates on DICOM CT and PET modalities, supporting ACR/NEMA DICOM 3.0 standards. Its core functionalities include receiving, storing, retrieving, displaying, and processing digital medical images. QTxI enables the identification and contouring of Regions of Interest (ROIs), facilitating quantitative and statistical analysis of full or partial-body scans through registration to template space. The tool provides 3D interactive rendering of images with highlighted ROIs and, at the time of its FDA clearance, included the Quantitative Total Bone Imaging (QTBI) module for identifying and measuring hot-spots on PET scans. AIQ Solutions has since evolved its technology, with TRAQinform IQ being a modification of QTxI, also FDA-cleared, focusing on quantifying changes in regions of interest over time to optimize late-stage cancer care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Evaluation and information management of digital medical images (DICOM CT and PET)
  • Display, registration, and fusion of medical images from multiple modalities
  • Identification and contouring of Regions of Interest (ROIs)
  • Quantitative and statistical analysis of full or partial-body scans
  • 3D interactive rendering of images with highlighted ROIs
  • Automated quantification of ROIs and changes in ROIs (via QTBI module)
  • Cloud-based HIPAA-compliant data pipelines
  • Automated report generation
  • Lesion-level longitudinal quantitative imaging
  • Radiomics and lesion heterogeneity metrics
  • Integration into existing clinical workflows

Use Cases

  • Optimizing late-stage cancer care
  • Monitoring treatment response in metastatic cancer (e.g., lung, lymphoma, prostate, bladder, head and neck, neuroendocrine system, melanoma)
  • Aiding oncologists/clinicians in adjusting therapies and optimizing clinical outcomes
  • Personalized medicine through analysis of individual patient treatment response
  • Quantitative assessment of early treatment response
  • Evaluating lesion response heterogeneity for prognostication

What Physicians Need to Know

Evidence Base
Quantitative Total Extensible Imaging (QTxI) is a software tool designed to aid in the evaluation and information management of digital medical images, specifically DICOM CT and PET scans. It supports the objective analysis of images, supplementing or replacing subjective evaluations. The tool's Quantitative Total Bone Imaging (QTBI) module identifies and measures hot-spots on PET scans. It aligns with the growing demand for quantitative imaging data to facilitate clinical decisions and the rigorous process of deriving, qualifying, and validating quantitative biomarkers. Established criteria like Response Evaluation Criteria In Solid Tumors (RECIST) are standard for tumor assessment, and quantitative imaging can enhance the reproducibility of such measurements.
Clinical Validation Studies
QTxI has received a 510(k) premarket notification from the FDA, classifying it as a 'System, Image Processing, Radiological' and indicating it is 'Substantially Equivalent' to a predicate device. This regulatory clearance implies a level of validation for its intended use in aiding medical professionals with image evaluation and information management.
Alert Fatigue Management
As QTxI performs automatic quantification of Regions of Interest (ROIs) and changes within them, it has the potential to generate alerts. Effective alert fatigue management strategies, such as prioritizing alerts, developing sophisticated and customized alerts, and incorporating end-user feedback, are crucial to ensure clinicians remain responsive to important notifications.
Differential Diagnosis Support
QTxI's capability for quantitative analysis of medical images, including automatic quantification of ROIs and changes, provides objective data that can support differential diagnosis. By offering precise measurements and insights into imaging features, it assists clinicians in distinguishing between conditions with overlapping symptoms and making more informed diagnostic decisions.
Guideline Update Frequency
The effectiveness of QTxI, particularly if it incorporates or aligns with clinical guidelines for image interpretation or tumor response (e.g., RECIST), depends on the timeliness of these underlying guidelines. Clinical practice guidelines are typically updated at least every two years, or more frequently if significant new evidence or advancements emerge.
Clinical Workflow Integration
QTxI is designed with platform features for workflow and integration, aiming to seamlessly fit into existing clinical environments. Effective integration into Electronic Health Records (EHRs) is critical for providing real-time, actionable insights at the point of care, reducing administrative burden, and optimizing provider time. This allows clinicians to access and utilize QTxI's quantitative imaging data directly within their patient charts.
Decision Audit Trail
While not explicitly detailed for QTxI, a robust clinical decision support tool typically includes a decision audit trail. This feature records all actions, modifications, and user interactions, providing accountability, transparency, and a historical log of how imaging evaluations and subsequent decisions were made. This is crucial for quality improvement and compliance.
Physician Tip

When utilizing QTxI, focus on integrating its quantitative outputs with your clinical judgment and other patient data. Pay close attention to alerts generated by changes in ROIs, but also be mindful of potential alert fatigue; customize alert settings if possible to prioritize critical information. Leverage QTxI's objective measurements to refine differential diagnoses and monitor treatment response more precisely, especially in oncology. Ensure the tool is well-integrated into your existing EHR to streamline workflow and avoid data silos. Regularly review the audit trail for insights into decision-making processes and for quality assurance.

Optimal performance of QTxI relies heavily on seamless integration with existing hospital information systems, particularly PACS (Picture Archiving and Communication Systems) for image acquisition and EHRs for patient context and documentation. Bidirectional data exchange is key to ensure QTxI can pull relevant patient history and write back quantitative analysis results and any generated alerts directly into the patient's record. Integration should support standardized imaging formats like DICOM 3.0. Future integrations could explore AI-driven differential diagnosis platforms, where QTxI's quantitative data could serve as a valuable input.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing — Not publicly available; contact vendor for custom pricing.
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

QTxI received FDA 510(k) clearance (K173444) on July 23, 2018, as a Class II medical device. It is intended to aid in the evaluation and information management of digital medical images by trained medical professionals. AIQ Solutions' subsequent technology, TRAQinform IQ, also has FDA clearance (K233998).
Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

What the Web Says

Quantitative Total Extensible Imaging (QTxI) by AIQ Solutions is an FDA-cleared software designed to help clinicians, particularly oncologists, assess cancer treatment response by analyzing imaging data over time. It provides novel information about the quantification of change in regions of interest (ROIs) and aids in optimizing therapy plans. The software integrates with serial radiographic images like PET and CT, offers cloud-based image upload, and generates comprehensive reports.

Overall: Mixed

Strengths

  • FDA-cleared for clinical use, ensuring regulatory compliance and reliability.
  • Aids oncologists and clinicians in optimizing therapy plans by providing quantitative assessment of cancer treatment response.
  • Offers quantitative assessment of lesion response heterogeneity.
  • Integrates with serial radiographic images (e.g., PET, CT) and PACS systems.
  • Provides cloud-based image upload and comprehensive reporting for oncologists.
  • Utilizes machine learning for skeletal and anatomic structure segmentation and threshold-based ROI identification and contouring.

Limitations

  • Limited public reviews from physicians, healthcare IT, or tech reviewers specifically for QTxI, making it difficult to gauge widespread user experience.
  • Some general AIQ reviews (not specific to QTxI) mention limitations in custom field setup for lower versions and time-consuming manual project code setup.
  • One general AIQ review noted a non-user-friendly platform and unhelpful customer support.
  • Lack of readily available detailed pricing information.
  • No specific reviews found on Reddit, G2, or Capterra directly addressing QTxI, making it challenging to assess broader user sentiment from these platforms.

Based on reviews from: HealthAidb, accessdata.fda.gov, Indeed.com, PubMed - NIH, G2, PMC - NIH, AuntMinnie, QIPCM, ClinicalTrials.gov, Capterra, Signify Research, Reddit, Trustpilot

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Quantitative Total Extensible Imaging (QTxI)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA
K173444. - 510(k) Premarket Notification - Quantitative Total Extensible Imaging (QTxI)
AIQ Solutions, Inc. received 510(k) clearance from the FDA for its Quantitative Total Extensible Imaging (QTxI) software on July 23, 2018. The software is intended to aid medical professionals in the evaluation and information management of digital medical images from multiple modalities like DICOM PET and CT.
2018-07
FDA
AIQ Solutions, Inc. July 23rd, 2018 Mr. Mitch Lewandowski Principal/Consultant EpiReg LLC 3428 John Muir Drive MIDDLETON WI
This FDA document details the 510(k) clearance for AIQ Solutions' Quantitative Total Extensible Imaging (QTxI) software, describing it as a tool for displaying, registering, and fusing medical images from various modalities, and for identifying and contouring Regions of Interest (ROIs) for quantitative analysis.
2018-07
Orthogonal
SaMD Cleared by the FDA: The Ultimate Running List
This comprehensive list of FDA-cleared Software as a Medical Device (SaMD) includes AIQ Solutions, Inc.'s Quantitative Total Extensible Imaging (QTxI), cleared on July 23, 2018, for radiology applications.
2024-10
Journal of Nuclear Medicine
Theranostics and artificial intelligence: new frontiers in personalized medicine
This article discusses the role of AI in theranostics and mentions AIQ Solutions, Inc.'s Quantitative Total Extensible Imaging (QTxI) as an FDA-cleared technology from 2018, capable of creating ROI contours for quantitative/statistical analysis and dosimetry.
2023-01
National Cancer Institute (NCI)
Wisconsin SPORE in Prostate Cancer - NCI
The Wisconsin SPORE in Prostate Cancer research outlines plans to utilize Quantitative Total Extensible Imaging (QTxI) for lesion-level assessment of treatment dynamics in men with metastatic castration-resistant prostate cancer (mCRPC).
2025-06
Scientia (Universidad Pablo de Olavide)
Sistemas electru00f3nicos de apoyo a la toma de decisiones clu00ednicas en pacientes con cu00e1ncer de mama, pulmu00f3n, colon-recto o pru00f3stata - Scientia
This academic work references Quantitative Total Extensible Imaging (QTxI) by AIQ Solutions as a software tool for evaluating and managing digital medical images, including DICOM CT and PET, for various medical professionals.
2021-04
Clarius
Clarius Ultrasound Scanner | AI-Powered Handheld Ultrasound ...
This article mentions Quantitative Total Extensible Imaging (QTxI) in a comparison with the Clarius Ultrasound Scanner, indicating QTxI's presence in the broader medical imaging technology landscape.
2026-04

Videos

Product demos, reviews, and walkthroughs for Quantitative Total Extensible Imaging (QTxI).

View all on YouTube

Frequently Asked Questions

QTxI is designed for seamless integration with existing PACS and EMR systems, providing quantitative insights directly at the point of care. It is particularly beneficial for monitoring chronic conditions, assessing treatment response in oncology, and for early detection of subtle pathological changes across various medical specialties.
QTxI holds relevant regulatory clearances (e.g., FDA 510(k) equivalent) for its diagnostic and quantitative analysis modules. The system employs robust, end-to-end encryption and adheres to strict data anonymization protocols to ensure full compliance with HIPAA and other pertinent data privacy regulations.
Unlike standard imaging, QTxI provides comprehensive, quantifiable metrics across multiple imaging modalities, offering a more objective and holistic view of disease progression or treatment efficacy. It surpasses many current AI tools by offering 'extensible' capabilities, allowing for integration of new algorithms and data sources as they emerge, enhancing its long-term utility and adaptability.
QTxI typically operates on a subscription-based model, with tiered pricing based on usage volume and integrated modules. While specific reimbursement codes are evolving, its quantitative outputs can support existing CPT codes for advanced imaging analysis and aid in justifying treatment decisions, potentially improving overall practice efficiency and patient outcomes.
While highly versatile, QTxI's accuracy can be influenced by suboptimal image acquisition quality or specific patient motion artifacts, similar to other advanced imaging platforms. There are no direct patient contraindications for the software itself, but standard contraindications for the underlying imaging modalities still apply.
QTxI provides objective, quantitative biomarkers and trend analyses that offer physicians a data-driven basis for diagnosis, prognosis, and treatment selection. Early clinical studies and ongoing trials demonstrate its potential to improve diagnostic accuracy, personalize treatment plans, and monitor therapeutic response more effectively, leading to better patient outcomes.
Comprehensive training programs are offered, including on-site sessions, online modules, and dedicated webinars, to ensure seamless adoption by physicians and technical staff. Ongoing 24/7 technical support and clinical application specialists are available to assist with any queries or optimization needs.

Compare Quantitative Total Extensible Imaging (QTxI)

VS
Quantitative Total Extensible Imaging (QTxI) vs Viz CTP
Clinical Decision Support & Reference Adjacent · 65/100
Tool A is designed for quantitative analysis and monitoring of medical images, primarily for oncology treatment assessment, focusing on detailed ROI evaluation. Tool B specializes in AI-powered disease…
VS
Quantitative Total Extensible Imaging (QTxI) vs ContaCT
Clinical Decision Support & Reference Adjacent · 60/100
Tool A (QTxI) specializes in quantitative analysis of medical images for detailed treatment monitoring, particularly in oncology, focusing on ROI quantification and change detection. Tool B (ContaCT) is…
VS
Quantitative Total Extensible Imaging (QTxI) vs Viz SDH
Clinical Decision Support & Reference Adjacent · 65/100
Tool A (QTxI) is a comprehensive platform for quantitative analysis and management of digital medical images, primarily focused on oncology treatment monitoring. In contrast, Tool B (Viz SDH)…
VS
Quantitative Total Extensible Imaging (QTxI) vs Viz Subdural+
Clinical Decision Support & Reference Adjacent · 65/100
QTxI offers a broad platform for quantitative analysis of CT and PET images, primarily aiding in general treatment monitoring and oncology. Viz Subdural+, conversely, is a highly specialized…

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.